Pharmaniaga Bhd 2025 IR
The report highlights Pharmaniaga Berhad's strategic progress and financial recovery in 2025, culminating in its successful exit from PN17 status. The group achieved a revenue of RM3.9 billion and a profit after taxation of RM50.7 million, driven by strong demand in the concession segment and cost-optimisation initiatives. On the sustainability front, the company improved its FTSE4Good ESG rating to 4.6 and advanced its biopharmaceutical capabilities, including local human insulin production. Additionally, Pharmaniaga expanded its solar energy installations and achieved zero workplace fatalities during the reporting period.
Company: Pharmaniaga Bhd
Sector: Health Care
Country: Malaysia
Year: 2025
Type: IR
Pages: 145
Pharmaniaga Bhd
Integrated Report
The report highlights Pharmaniaga Berhad's strategic progress and financial recovery in 2025, culminating in its successful exit from PN17 status. The group achieved a revenue of RM3.9 billion and a profit after taxation of RM50.7 million, driven by strong demand in the concession segment and cost-optimisation initiatives. On the sustainability front, the company improved its FTSE4Good ESG rating to 4.6 and advanced its biopharmaceutical capabilities, including local human insulin production. Additionally, Pharmaniaga expanded its solar energy installations and achieved zero workplace fatalities during the reporting period.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2025
Reporting Period
Jan 1, 2025 - Dec 31, 2025
Fiscal Year
2025
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Scope 3:
Energy Consumption
Water Consumption
Total Waste
Women on Board
Women in Management
Workplace Fatalities
Employees